INTRODUCTION
A Phosphate Centric Forum, supported by Genzyme Corporation, was held on 24-25 June, 2010 at the Sheraton West Park Hotel, Munich, Germany, in which 25 medical and scientifi c experts in the fi eld of chronic kidney disease-related mineral and bone disorder (CKD-MBD) met to present and discuss the central role of phosphate in the development of CKD-MBD, on which research has now celebrated its 50th anniversary.
Phosphate plays a central role in the pathophysiology of CKD-MBD and the progression of CKD and contributes to the disproportionate cardiovascular risk faced by patients with CKD. Adaptation of nephrons attempting to preserve phosphate homeostasis requires endocrine tradeoff s that fuel adverse events of hyperphosphatemia in CKD-secondary hyperparathyroidism, calcium and vitamin A roundtable discussion included the pathophysiology of CKD-MBD, discoveries such as the vitamin D receptor, calcium-sensing receptor, fibroblast growth factor (FGF)-23, and currently available treatment options, as well as future needs regarding research and management of this disorder.
Discussants concluded that placebocontrolled trials are needed in CKD stages 2-4 to investigate the eff ect of phosphate and phosphate binders on mortality. Various other endpoints were suggested, such as bone disease, progression of CKD, and cardiovascular events. Ongoing studies investigating a broad range of cardiovascular surrogates are due for completion in 2011. Monitoring methods using the less expensive option of phosphate and creatinine are preferred over FGF-23 at the present time, and studies investigating patients over 50-55 years of age with high levels of FGF-23 have been suggested to provide the most valuable data. However, it was generally agreed that FGF-23 may be a uremic toxin, which would support development of anti-FGF-23 strategies in the future.
Development of other therapeutic targets, including biomarkers that assess function of NaPi2a, b, or c (to decrease the reabsorption of phosphate) or Klotho, is considered to be challenging but should remain a long-term goal. The effects of infusion of soluble Klotho, how the bone senses phosphate, and why high levels of FGF-23 are found in non-renal organs are other areas of interest for future research.
Th is supplement provides a review of fi ve of the topics discussed during the forum: Dr Slatopolsky presents the history of the intact nephron hypothesis and its current implications; Dr Confavreux presents a very new facet of the bone, from a reservoir of minerals to a regulator of energy metabolism; 
